Use of Telemedicine for Buprenorphine Inductions in Patients With Commercial Insurance or Medicare Advantage
- PMID: 34989798
- PMCID: PMC8739765
- DOI: 10.1001/jamanetworkopen.2021.42531
Use of Telemedicine for Buprenorphine Inductions in Patients With Commercial Insurance or Medicare Advantage
Abstract
This cross-sectional study examines the use of telemedicine for buprenorphine inductions among individuals with commercial insurance or Medicare Advantage during the temporary repeal of the Ryan Haight Act requirement of in-person evaluation before prescribing buprenorphine during to the COVID-19 pandemic.
Conflict of interest statement
Figures
References
-
- Warner pushes for release of long-delayed telehealth guidance to expand access to medical treatment . News release. Mark R. Warner. May 3, 2021. Accessed August 18, 2021. https://www.warner.senate.gov/public/index.cfm/2021/5/warner-pushes-for-...
-
- Implementation of the Ryan Haight Online Pharmacy Consumer Protection Act of 2008. Federal Register. Accessed August 18, 2021. https://www.govinfo.gov/content/pkg/FR-2009-04-06/pdf/E9-7698.pdf - PubMed
-
- COVID-19 information page. US Department of Justice Drug Enforcement Administration. Accessed August 18, 2021. https://www.deadiversion.usdoj.gov/coronavirus.html
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
